Stem Cell Therapy for Type 1 Diabetes Mellitus
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01143168 |
Recruitment Status : Unknown
Verified June 2010 by Cellonis Biotechnology Co. Ltd..
Recruitment status was: Not yet recruiting
First Posted : June 14, 2010
Last Update Posted : June 14, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Type 1 Diabetes Mellitus | Biological: autologous bone marrow mononuclear cells and umbilical cord mesenchymal stem cells | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 24 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Pilot Study on Transplantation Therapy Using Autologous Bone Marrow Mononuclear Cells and Umbilical Cord Mesenchymal Stem Cells in Patients With Type 1 Diabetes Mellitus |
Study Start Date : | August 2010 |
Estimated Primary Completion Date : | August 2011 |
Estimated Study Completion Date : | December 2011 |

- Biological: autologous bone marrow mononuclear cells and umbilical cord mesenchymal stem cells
First Transplantation: after finishing all required examines according to protocol on Day 0, ABM-MNCs + UCMSCs are transplanted through pancreas artery percutaneously; Second Transplantation: after finishing all required examines on Day 7±1, BM-MNCs UCMSCs are transplanted intravenously; Third Transplantation: after finishing all required examines on Day 14±2, BM-MNCs + UCMSCs are transplanted intravenously.
- Rate of reducing exogenous insulin requirement; Hemoglobin A1c; Fast blood glucose (FBG) and postmeal blood glucose (PBG); C-peptide levels. [ Time Frame: 1 year ]Rate of reducing exogenous insulin requirement compared with baseline. Hemoglobin A1c. Fast blood glucose (FBG) and postmeal blood glucose (PBG). C-peptide levels.
- Serious adverse event frequency and severity [ Time Frame: 1 year ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Free will taking part in the study and ability to provide written informed consent.
- Confirmed diagnosis of type I diabetes for at least 2 years
- Insulin-dependent.
- Age 18-50 years, Male/Female.
- FBG≥7.0 mmol/L, and HbAc1≥7%.
- Not pregnant or nursing.
- Negative pregnancy test.
- Fertile patients will use effective contraception.
Exclusion Criteria:
- Presence of acute diabetic complications in the acute stage as recent myocardial infarction, recent cerebral vascular accident (CVA) or acute renal failure.
- Severe concurrent medical condition (e.g. lung disease, or hematopoietic dysfunction, or liver dysfunction).
- Active infection requiring treatment.
- Known immunosuppressive disease, e.g. HIV infection, or hepatitis B or C infection.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01143168
China | |
Armed Police General Hospital, P. R. China | |
Beijing, China, 100085 |
Principal Investigator: | Shi X Y, M.D. | Armed Police General Hospital, P. R. China |
Responsible Party: | Cellonis Biotechnology Co. Ltd., Others |
ClinicalTrials.gov Identifier: | NCT01143168 |
Other Study ID Numbers: |
Cellonis-CR-1.3 |
First Posted: | June 14, 2010 Key Record Dates |
Last Update Posted: | June 14, 2010 |
Last Verified: | June 2010 |
stem cells; diabetes mellitus; treatment. |
Diabetes Mellitus Diabetes Mellitus, Type 1 Glucose Metabolism Disorders Metabolic Diseases |
Endocrine System Diseases Autoimmune Diseases Immune System Diseases |